Autopsy report · NCT05517226
Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment
Cause of deathFunding or business, also safety
“Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.”
Life of this trial
- Ran for about 6 months before it stopped.
- 24 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Hepatic Impairment
- Interventions
- Cotadutide
- Participants
- 24
- Sites
- 3
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.